Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Case Reports Cancer Bladder Cancer NAME/Y.I. AGE/39 SEX/Female AREA/unknown History of Past Diseases and Treatments The patient developed rheumatoid arthritis while she was studying to be a dentist at a dental school. She opened her own dental clinic at the age of 29 and had a busy practice. She had severe hematuria in February 1999 and was admitted to the urology department at a nearby hospital for examination. Histopathological tests revealed bladder cancer. She was recommended to have an operation, but she refused due to QOL issues. She chose to undergo treatment mainly consisting of alternative medicine, trying various options. On June 5, she visited this hospital for treatment. She was immediately put on a restricted diet based on semi-fasting. She was also recommended to take a daily dose of 4-5 g of Rice Bran Arabinoxylan Compound (RBAC) to enhance immunity and plant enzymatic foods to improve her blood profile. Pain upon urination began to subside two weeks after the start of treatment. In early July, one month after initiating treatment, hematuria was lighter, suggesting a rapid reduction in the size of the tumor. The value of the tumor marker NMP-22 (normally 12 or less) decreased from 58 on May 25, to 10 on July 28. Evaluation The bladder cancer decreased in size over a short period due to treatment with a restricted diet and immunopotentiation. It ultimately disappeared, as determined by tumor marker test results. The patient’s young age and great self-healing ability may have contributed to this improvement. However, since adherence to a conventional lifestyle is likely to cause a recurrence and new tumor growth, the patient needs careful follow-up, including health guidance. Breast Cancer NAME/K.T. AGE/39 SEX/Female AREA/Japan NAME/M.D. AGE/74 SEX/Female AREA/Japan Clinical Record and Treatment Two patients with breast cancer took 3g of Rice Bran Arabinoxylan Compound (RBAC) per day continuously in order to confirm the effectiveness of RBAC. Patient K.T. age 39, had surgery on her right breast due to cancer. One and a half years after the operation, she had a combined treatment of chemotherapy and RBAC at a hospital in Kochi prefecture, Japan. Tumor marker CA15-3 was 268 at the beginning. The rise in the marker has been inhibited by the combined therapy and she has since maintained her health and enjoys a normal life, although she continues to visit the hospital on a regular basis. She took RBAC from February 24, 1997 to December 3, 1998. Patient M.D., 74 years old, arrived at the hospital with a tumor protruding from her breast like a cauliflower. The tumor markers were 63.4 for CEA and 14.6 for CA15-3 at that time. She was hospitalized on August 2, 1997 when she started taking RBAC at a dose of 3 grams a day. On October 2, 1997, the tests showed that the markers stayed at 15-3 65.1 for CEA and 20.1 for CA. Surgery was performed at her request in January 1998. The patient continued to 1 take RBAC and the marker CEA declined to 3.5 as of February 10, 1999. RBAC seemed to help prevent cancer recurrence and she has maintained good health since. The period that she took RBAC was from August 2, 1997 to February 10, 1999. Patient: M.D., 74 years old 70 63 CA15-3 65 64 60 Tumor markers CEA 50 40 30 14 20 20 21 10 3.5 0 8/2/1997 10/2/1997 1/5/1998 surgery 2/10/1999 Evaluation This small-scale clinical study involving two female patients seems to confirm the effect of RBAC for breast cancer. Either case, tumor markers did not increase during the period of RBAC administration. RBAC did inhibit the growth of tumors. It has prolonged the life of each patient since all the patients have continued to maintain a healthy and stable condition. NAME/C.E. AGE/51 SEX/Female AREA/U.S.A. Clinical Record and Treatment A 51 year old patient in California found a tumor in her left breast, as confirmed by biopsy at a hospital on December 19, 1994. She first took hormone therapy and radiotherapy, which were unsuccessful. On March 7, 1995, she began taking 3 grams of Rice Bran Arabinoxylan Compound (RBAC). Her NK cell activity nearly doubled as compared to baseline, and a mammogram taken on July 31, 1995, revealed the absence of tumors, not even a benign one. 100 90 NK-cell Activity (%) 80 70 66.8 66 11/1/1995 5/1/1996 1/1/1997 55 60 40.8 50 40 65 36 30 20 10 0 03/1995 baseline 4/1/1995 5/1/1995 2 Another test done in January 1997 did not detect a tumor, and she has continued to take RBAC to prevent relapses. Evaluation After receiving hormone therapy and irradiation therapy, the patient took RBAC as a measure to prevent cancer recurrence. While taking RBAC, the patient's NK cell activity increased gradually and now the patient maintains twice the level of NK cell activity as compared to the initial levels. This improvement is thought to have helped prevent a recurrence. NAME/M.L. AGE/50 SEX/Female AREA/U.S.A. Clinical Record and Treatment On August 3, 1991, a tumor was discovered in the patient's left breast during a breast examination. The patient started taking 3 g of Rice Bran Arabinoxylan Compound (RBAC) per day for immunotherapy on September 3, 1992. Subsequently, a CAT scan performed on March 13, 1993 found no tumor. The patient's right breast was also normal and healthy, as indicated by a mammogram conducted on January 26, 1995. 100 90 NK-cell Activity (%) 80 72.6 70 59.6 58.9 58.7 6/1/1993 9/1/1993 12/1/1993 58 60 63 50 40 30 20 10 5 0 01/1992 baseline 1/1/1993 3/1/1993 2/1/1994 Evaluation The administration of RBAC would have helped to heal the patient's breast cancer within two years. Her NK cell activity increased rapidly and remained at a high level during RBAC administration. NAME/M.M. AGE/48 SEX/Female AREA/Japan Medical History The patient noticed a swollen lymph node on the left side of her neck. She visited a nearby hospital for a complete medical checkup, which revealed a tumor in her left breast and the swelling in her neck was diagnosed as a metastatic lesion. It was determined to be inoperable and she was put on chemotherapy with three anticancer drugs (Adriamycin, 5FU and cyclophosphamide). The tumor in her left breast was involute and the lymphatic metastasis shrank temporarily. Later, the metastasis resumed and the tumor marker did not decrease, so the patient received four more sessions of chemotherapy. In January 2000, a weekly infusion with docetaxel wettable powder (Taxotere) was initiated and maintained until July of that year because there was an increase in lymphatic metastasis and tumor 3 maker values. On January 18, the patient visited our clinic seeking immunopotentiation therapy. On January 28, she began to receive massive weekly infusions of vitamin C and Chinese medicine (Hochuekkito 7.5 g/day), as well as Rice Bran Arabinoxylan Compound (RBAC) at a dosage of 3 g per day (1 g three times daily) as immunopotentiation therapy. In June of the same year, shrinking of the lymph swelling was confirmed. Hormone therapy (Hysron progesterone preparation) replaced Taxotere in August. Since then, there has been no recurrence or metastasis as confirmed by radiography, CT and ultrasonography, although tumor markers have been fluctuating. Evaluation After the patient began taking RBAC as part of her immunopotentiation therapy, in addition to chemotherapy, NK cell activity increased and tumor size decreased. Eight months after treatment with RBAC, NK cell activity increased more than two-fold, which seemed to have contributed in preventing recurrence. NAME/J.B. AGE/46 SEX/Female AREA/Germany 02/1998: Diagnosis: Breast cancer, T3 (tumor >5cm), G2, plum-sized primary tumor; could not be removed completely from healthy tissue. The patient rejected the removal of lymph nodes as well as chemotherapy and radiation. Alternative treatment: Mistletoe therapy, Vitamin C infusions, change in diet, orthomolecular nutrients, detoxification by fasting for 42 days. 10/2000: Removal of a recurrence. 01/2001: Five times whole-body hyperthermia treatment, detection of low Natural Killer Cell activity. 01/2001: Test results after hyperthermia period: (> 25) NK/Ctx (cytotoxicity); basal 5% (> 40) NK/Ctx; IL-2 stim 13%. Conclusion: Despite high-dose vital nutrient therapy, Vitamin C infusions, mistletoe therapy, change in diet and whole-body hyperthermia, there was no increase of Natural Killer Cell activity. 06/2001: Initiate treatment of Rice Bran Arabinoxylan Compound (RBAC), 3g/day. Test results 25.06.01 (>25) NK-CTX (cytotoxicity); basal 28% (>40) NK-CTX; IL-2 stim 31%. Result 14.07.01 (>25) NK-CTX; basal 36% (>40) NK-CTX; IL-2 stim 38%. Conclusion: Increase of Natural Killer Cell activity from 5% to 36% within 6 weeks. Since then the patient has been in good physical and psychological condition. Additionally, according to the latest measurement in November, 2011, her haemogram (CBC) is optimal. Tumor recurrence hasn’t been detected since October 2004. To support her immune system the patient occasionally does a round of RBAC treatment consisting of 1-3g RBAC daily for several weeks. Colon Cancer NAME/S.B. AGE/64 SEX/Male AREA/Japan History of Past Diseases and Treatments In December 1998, the patient found large quantities of blood in his stool, so he visited a nearby hospital to undergo a colonoscopy. As a result, he was diagnosed with colon cancer. He was recommended, but refused, a surgical 4 operation and he then visited this hospital in January 1999. Although he was also recommended to have surgery at this hospital, he instead strongly requested a conservative treatment consisting mainly of immunotherapy to prevent further cancer growth. He was treated with a restricted diet and a combination of the immunopotentiator Rice Bran Arabinoxylan Compound (RBAC), additional health foods, growth hormone and thymus hormone. RBAC was given in a six-day cycle, with four successive days of dosing at 5 g daily and then two days off. After one year of treatment, he noticed his stool was thinning and thought the cancer was growing. After a complete medical checkup, it was found that the cancer was not growing but had necrotized completely. The stool was thinner because the mass of the necrotized cancer lesion was occluding the colon. Evaluation The colon cancer was progressive and required surgery. Considering QOL, the patient chose to undergo a treatment that would enhance his self-healing potential. RBAC was used to play a leading role in enhancing immunopotency. Lung Cancer NAME/S.K. AGE/67 SEX/Male AREA/Japan Clinical Record and Treatment A male Japanese patient, aged 67, lost substantial weight and suffered from a hacking cough with sputum, which brought him to the department of Respiratory Medicine and Surgery at a hospital in Osaka, Japan in August 1996. At the examination he was diagnosed with lung cancer complications and pulmonary tuberculosis. In October 1996, he was first treated with antibiotics for pulmonary tuberculosis, and then with irradiation therapy for lung cancer. In December of that year, a tumor was removed by resection of the lower half of his right lung. In January 1997 the patient left the hospital. Five months later, he felt pain in his right thoracic region and upon examination, multiple bone metastases were found. Tumors then spread all over the patient’s body, with the primary site in the ribs of his right thoracic region. Three grams a day of Rice Bran Arabinoxylan Compound (RBAC) were administered with an analgesic morphine. Six months after taking RBAC, the dosage of morphine was gradually reduced as his pain subsided. In June 1998, his pain ceased and he was able to discontinue morphine. The tumor marker was 16.8 in June 1997 at the start of RBAC administration, which declined to 7.6 in December 1997 and 6.7 in June 1998. Significant improvement was observed with a bone scintigram. Metastasis to bone had clearly lessened. 20 CEA 16.8 10 7.6 6.7 0 6/1/1997 12/1/1997 5 6/1/1998 Changes caused by RBAC Treatment The patient felt the type of pain in his right thoracic region change 1 month later after taking RBAC, and the pain had obviously lessened 6 months later. Evaluation In this case, metastasis had developed very rapidly and was gradually slowed and shrunk after RBAC was administered. As of June 1998, the tumor marker was still higher than the normal level, but a continuous intake of RBAC would lead to further improvement and eventual remission. RBAC treatment was used in a very similar case of lung cancer involving a 77 year old female patient with a very similar treatment, leading to an improvement in bone metastasis and a reduction in pain. NAME/A.G. AGE/unknown SEX/Male AREA/Germany 28/07/2005: Medical evaluation: strong suspicion of a bronchial carcinoma located centrally in the left main bronchus, space occupying size of 3.5 x 3 cm. 08/09/2005: Start RBAC (Rice Bran Arabinoxylan Compound) treatment: 3g daily for one month, continue with 1g daily thereafter. 08/09/2006: First cycle of chemotherapy with Taxol and Cisplatin. 16/09/2005: Histopathology results: undifferentiated non-small cell carcinoma, G3 (high grade), suspicion of a bronchial carcinoma located centrally on the left main bronchus. 16/09/2006: Initiate thirteen cycles of induction chemotherapy with Paclitaxeland Cisplatin II radiochemotherapy. 28/09/2005: Diagnosis: Bronchial carcinoma left side (NSCLC), T4 (invasive), NO (no lymph nodes), MO (no distant metastasis). 29/11/2005: ESPATÜ-study: neoadjuvant induction chemotherapy, radiochemotherapy with Paclitaxel and Cisplatin II. 21/12/2005: Initial neoadjuvant radiochemotherapy proceeded without complications. Later will require definitive radiochemotherapy up to 71Gy (ESPATÜ study with 88 participants). Rehabilitation therapy to start in February, 2006 (previous skull-MRI). Prophylactic whole-skull radiation. 14/06/2006: Diagnosis: Central infarction (after radiation) in lower lobe, left side. Non-small cell bronchial carcinoma left lung, ED 08/05 (T4, NO, MO). COPD Therapy: transthoracic swaged left thoracic. Radiochemotherapy until 02/2006. 19/09/2006: Thoracic CT with contrast agent. Technique of investigation: lateral topogram, spiral CT. Result: still 2 x 1.5 cm sized, smooth, circumscribed liquid mass, left dorsolateral, situated in the apical segment of the lower lobe. Most likely shrinking scar, necrotic remains of tumor or shrinking abscess cavity. 6 The original large tumor in the left, central lung is almost imperceptible after chemotherapy and radiation. 10/11/2006: Imaging: FDG-PET/CT native and contrast agent from 02.11.06. Question: Recurrence? Evaluation: No evidence of vital tumor manifestation. The morphologically detectable lung lesions are most likely post-radiogenic or post-inflammatory induced. End of 2007 Only 2 out of 88 participants from the ESPATÜ study are still alive. 02/2008: Patient is free of pain and continues with 250mg RBAC daily. 01/2012: The patient is still well and the sole survivor of the study. Nephroblastoma NAME/T.J. AGE/unknown SEX/unknown AREA/Slovakia Medical History: History: Grandfather had operation for Grawitz renal tumor, rectosigmoid cancer, and is presently in remission. Personal History: Child from first pregnancy, p.h. 3170g, length 51cm, Abgar score 10. Social History: Good Nutrition and Elimination: Good appetite, urination without difficulty, haematuria, regular bowel movement Evidence of Abuse: Negative History of Allergies: Negative CHS: A 4 ½ year old patient was admitted to the oncology clinic with diagnosis of suspicious Morbus Wilms syndrome. 48 hours ago the kindergarten teacher noticed macroscopic haematuria (blood in urine) and on the following day the mother also observed the presence of haematuria in the boy, without dysuria (painful urination). The patient was then examined by the urologist when ultrasound screening indicated a suspicious left kidney tumor. Additional CT examination was carried out with contrast medium administration, confirming a left kidney tumor of possible malignant etiology. The size of the kidneys were 4.5 cm and tumor 7.5 cm. Because the tumor originated on the upper region of the kidney, no asymmetry was visible (i.e. bulging of the abdominal cavity), which is one of the most common initial symptoms of this type of cancer in young children. Preoperative period The patient was admitted to the Oncology Clinic DfN the following day where preoperative chemotherapy was administered to localize the nephroblastoma (kidney tumor) according to the protocol from the SIOP 2001 nephroblastoma trial with the drugs 4x Vinkristin, 2x Cosmogen and 3x Aktinomycin. Preoperative chemotherapy was administered to reduce and limit the growth of the tumor because of surrounding critical organ and tissue structures. The administration of chemotherapy for a 6 week period did not reduce the tumor size, but the effect was sufficient considering the surrounding area, allowing for preoperative preparation. During the administration of preoperative chemotherapy there was an unexpected rapid decrease in leukocytes from the original 8.9 to 1.5 g/L. Because of this low leukocyte level the operation was not possible. Transfer factor, an immunostimulant, was given to the patient and after consulting with the doctor, the mother started giving him Rice Bran Arabinoxylan Compound 7 (RBAC). There was a significant rise in leukocytes within a few days, from the original 1.5 to 4.0 g/L. Because of the success of the treatment, the operation for nephrectomy (kidney removal) and epinephrectomy (adrenal removal) th was performed on the 7 day of RBAC administration. The transfer factor was administered only once. Operation Patient was given general anesthesia. Laparotomy procedure to remove his left kidney and left adrenal. Postoperative period - chemotherapy The operation was performed on 21.6.2005 and 21 days later, after review of histology results, postoperative chemotherapy was started. Considering the fact that histology results indicated intermediate risk, stage II, the patient qualified to be included in an internationally coordinated study whose center is located in Amsterdam. By means of random selection, he was placed in the group that received chemotherapy with the lowest dosage of cytostatics (to prevent multiplication of tumor cells) in combination with two drugs, Vinkristin and Cosmogen, instead of the standard combination of 3 drugs. After 6 weeks of chemotherapy the patient felt sick. According to the child´s own words it was as if the disease had not subsided. Leukocyte values during this period were between 6- 9 g/L. After evaluating the clinical condition of the patient, chemotherapy was modified to the standard combination of Vinkristin, Cosmogen and Doxorubicin, administered once per week, followed by an additional Doxorubicin injection over the next 6 weeks. The result of the strong immunosuppression was a decrease in leukocytes from 6 to 0.8 g/L over the course of less than two weeks. Chemotherapy was subsequently suspended due to leukopenia (significantly low white blood cell count). Starting from this point, RBAC was added to the treatment in dosages of 1000 mg /day, which was calculated based on a weight of 15 kg. During the course of the week, the CBC (complete blood count) improved as a result of the rise in leukocytes, enabling chemotherapy to proceed according to schedule. RBAC was not reduced during chemotherapy and thanks to the immunostimulatory effect of the of the nutritional supplement, the child was able to undergo chemotherapy without interruption or delay due to leukopenia. Despite significant immunosuppression during the administration of chemotherapy and RBAC, the child was not overcome by any serious bacterial or viral infection. RBAC was given to the patient at the stated dosage for a total of 9 months, with an obvious positive clinical effect documented by consistent laboratory results. Reconvalescence period After the completion of chemotherapy in February 2006, the patient was given RBAC for an additional 18 months in reduced dosages of 500 mg/day. During this period the patient was healthy and attended compulsory preschool without acquiring any bacterial or viral infections. Final summary The present case study of an oncology patient whom was administered the nutritional supplement RBAC during and after chemotherapy provides sufficient clinical evidence to support the efficacy of the preparation. The immune enhancing effect of the dietary supplement RBAC, specifically on NK (natual killer) cells and TNF (tumor necrosis factor), enabled the patient to continue with chemotherapy without any delay caused by accompanying leukopenia. The more than 100,000 times increase in the number of NK cells lead the charge against the surviving tumor cells in the patients blood. It can be concluded, based on wide clinical experience backed by laboratory findings, that the 8 combination of RBAC with targeted chemotherapy is a treatment that can be used therapeutically for solid tumors. Ovarian Cancer NAME/unknown AGE/53 SEX/Female AREA/unknown There is an interesting case of combination therapy using chemotherapy and Rice Bran Arabinoxylan Compound (RBAC) together which resulted in shortening the period of achieving a complete clinical remission to just two months. It would normally take 3 to 4 months on average to heal a patient of cystadenoma with only chemotherapy. A female patient was 53 years old, when on February 11, 1993 she was diagnosed with ovarian cancer. Her clinical symptoms included swelling of the breasts and abdominal distention. Pathological findings were high grade serous papillary cyst adenocarcinoma with areas of undifferentiation and frequent mitosis. The tumor involved both ovaries, with multiple peritoneal implants. The lymph nodes were tumor free. Cytospin and button section peritoneal fluid showed malignant cells. The patient underwent surgery, followed by a course of chemotherapy consisting of cysplatin and 5FU. Concurrently, RBAC was administered orally in a dose of 3 grams a day. The progress of her condition was monitored by sequential determinations of CA-125 (tumor marker). The baseline CA-125 after surgery was 327 U/ml. A significant reduction in the level of CA-125 was found 3 weeks after the combination therapy and a further reduction in CA-125 occurred 6 weeks after the treatment. The antigen level reached that of controls (0-35 U/ml). CA-125 maintained at low levels in subsequent examinations; 23 and 18 U/ml at 9 and 12 weeks respectively, after the treatment. Baselines of NK cell activity for the patient were 2.9, 7.4 and 15.2% at E:T ratios 12:1, 25:1 and 50:1 respectively. NK cell activity was further monitored at different intervals after the combination therapy using chemotherapy and RBAC. The results showed a significant enhancement in NK cell activity as early as 3 weeks after the treatment. An increase in NK cell activity was observed at all E:T ratios as follows; 6.6% at 12:1, 20.2% at 25:1 and 37.4% at 50:1. NK cell activity maintained a high level at one month after the treatment and an additional increase was achieved at 4.5 months, namely, 11.7, 41.1 and 72.6% at 12:1, 25:1 and 50:1 respectively. Also, a flow cytometry study was conducted to evaluate the percentage of CD56 cells. Results showed no significant change in NK cells after the treatment as compared to NK cells before the treatment. Prostate Cancer NAME/C.J. AGE/68 SEX/Male AREA/U.S.A. Clinical Record and Treatment An American patient aged 68 was diagnosed in July, 1995 at a hospital in California. Two types of chemotherapy treatments were initiated immediately, but were unsuccessful. An examination conducted on August 25, 1995, revealed a Gleason score of 9. There was no significant improvement despite the chemotherapy. In January, 1996 he started taking 3 grams of Rice Bran Arabinoxylan Compound (RBAC) per day. In April, 1996 the patient had a cryoprostatectomy without hormone therapy. He recovered his ability to ejaculate on November 10, 1996. His NK cell 9 activity increased one year after the RBAC treatment had started. His tumor marker PSA level shows that he is in full remission now. 90 80.3 NK-cell Activity (%) 80 70 60 44.5 50 40 33.7 35.5 01/1996 baseline 4/1/1996 30 20 10 0 5/1/1996 12/1/1996 Evaluation This patient took RBAC only after he discovered that the chemotherapy was unsuccessful. Three months later, the tumor had involuted, making it possible to remove by means of cryoprostatectomy. It seemed that RBAC helped the patient to restore his ability to ejaculate. His NK cell activity has since been maintained at a high level by the administration of RBAC. The results suggest that in this case, RBAC had positive effects in inducing involution of the tumor and in preventing tumor recurrence. Case Reports NAME/T.H. Leukemia AGE/26 SEX/Female AREA/Germany 17/11/2004: Referral to hospital with a haemoglobin (Hb) value of 5.5. Bone marrow puncture resulting in diagnosis of ALL (Pro-B-ALL) with 97% B-cells. 18/11/2004: Transfer to the intensive oncological care unit. Hemoglobin value of 4.6. 19/11/2004: Start cortisone treatment, daily EPO injections. 20/11/2004: Further deterioration of the patient’s general condition, Hb-value declines to 3.7. Initiate chemotherapy (Vincristin). 21/11/2004 Second round of chemotherapy (VCR, dexamethasone, 50mg Daunoblastina). 22/11/2004: Hb-value 3.5; leukocytes 1.3; thrombocytes 4. Administration of G-CSF (granulocyte-colony stimulating factor). 24/11/2004: Absolute bed rest prescribed until 25.11.2004. Increasing signs of fatigue and exhaustion. Administer 10 oxygen. 26/11/2004: Hb-value declines to 2.1. Conversation with medical staff because of acute life-threatening danger. Third round of chemotherapy. 27/11/2004: Deterioration of general condition. 28/11/2004: Transfer to single bedroom (isolation), Hb-value declines to 1.4. Initiate intake of RBAC (Rice Bran Arabinoxylan Compound) (nutritional supplement) 3g per day (at patient’s own risk). 29/11/2004: EPO-injection advanced for one day. 01/12/2004: Hb-value remained stable at 1.4. 03/12/2004: Fourth round of chemotherapy. 05/12/2004: Hb-value increases to 1.9. Thrombocytes octuplicate (increase eightfold) to 32.0. Discontinue cortisone treatment. 06/12/2004: End of isolation. EPO-injection (Aranesp). 07/12/2004: Removal of IV tubes, as sufficient fluids can be taken orally. 09/12/2004: Bone marrow puncture; blasts are <5%, extreme bone marrow regeneration and increase of blasts. 10/12/2004: Fifth round of chemotherapy. 13/12/2004: Transfer patient to the regular unit. Hb-value increased to 4.3. 16/12/2004: Hb increased on 5.0, thrombocytes to 180000. 17/12/2004: Sixth round of chemotherapy. 18/12/2004: Hb increased to 5.8; thrombocytes are 225000; leucocytes are 10.9. 20/12/2004: Hb 6.1; thrombocytes are 220000; leukocytes 5.9. Waiting for increase of Hb-value to at least 90g/l, preferably greater than 100g/l, then continuation of the treatment. 28/12/2004: Continuation of the treatment. 24/01/2005: Hb 12.5; thrombocytes 289000; Leukocytes 4.9. 11 25/01/2005: Initiate ALL induction therapy stage 2 (Endoxan 1670, Alexan 1000, Purinethol 100 mg daily) + Granozyte + 2x 15mg MTX (into bone marrow) + for the protection of the bladder: Uromitexan 400mg/h 0-4-8. 29/01/2005: Adjourn chemotherapy due to headache and recurrent vomiting (depending on the position). 28/02/2005: Continuation of chemo induction-stage II. 02/03/2005: Hb 8.7; thrombocytes 204000; leukocytes 24.6 (G-CSF). 04/03/2005: End of therapy. 08/03/2005: Start with prophylactic radiation of the skull at 12 Gy (gray unit) 6x, at the radiation clinic in Ludwigsburg. 18/03/2005: Hb 8.6; thrombocytes 70000; leukocytes 2.8. 23/03/2005: Inpatient admission, referral to hospital RBK in Stuttgart. 24/03/2005: Hickman implantation. Laboratory: Hb 6.8; thrombocytes 64000; leukocytes 1.6. 11/04/2005: Whole-body radiation in Heidelberg, TBI 12Gy. 12/04/2005: Laboratory: Hb 12.8; thrombocytes 78000; leukocytes 3.58. 15/04/2005: Laboratory: Hb 11.6; thrombocytes 64000; leukocytes 3.3. 15/04/2005: Admitted to the RBK in Stuttgart. 16/04/2005: Myeloablative therapy with cyclophosphamide (120mg/kg body weight). Start with high-dosed chemo Endoxan. 18/04/2005: Discontinue RBAC intake. 6 19/04/2005: Stem cell transplantation (transplanted number of cells: 5.04 x 10 /kg body weight). CD34 pos. cells, GvHD. Prophylaxis: CSA mirror adapted, MMF transplant complications: grade IV neutropenia, grade IV thrombocytopenia, grade III anemia, "minor bleeding", gross hematuria, multiple petechia, subarachnoidal hemorrhage (mouth). 09/05/2005: Hb 11.1; thrombocytes 151000; leukocytes 4.0. Medications: folic acid, Multibionta, Aranesp, Pantoprazole, magnesium preparation, Levofloxacin, Metronidazole, Fluconazol, Cyclosporin (Sandimmun), Mycophenolate Mofetil (Cellsept). 09/01/2006: End of immunosuppression, discontinuation of Sandimmun. 12 13/02/2006: Hb 10.7; thrombocytes 131000; leukocytes 4.0. Start with RBAC 1g daily (for about 3 months). 09/03/2006: Hb 11.2; thrombocytes 143000; leukocytes 4.8. 20/04/2006: Hb 11.7; thrombocytes 178000; leukocytes 4.7. 09/05/2006: Discontinue RBAC intake. 31/05/2006: Hb 11.3; thrombocytes 144000; leucocytes 4.1. 01/06/2006: Return to work for 15 h / week. 05/10/2006: Hb 12.4; thrombocytes 225000; leukocytes 4.4; ESR 40/80. 07/10/2006: Fever up to 39.5°C. 20/10/2006: RBAC- 4 tablets of RBAC (=2g) twice daily. After 3 days, 1 x daily (=1g) (in total 50 tablets). 13/11/2006: Hb 11.8; thrombocytes 131000; leukocytes 4.3. Liver enzyme parameters continue to decline. 20/02/2008: Patient feels very well and healthy, blood values are optimal. Case Reports NAME/O.T. Lymphoma AGE/75 SEX/Female AREA/Japan Clinical Record and Treatment In November 1998, a 75 year old Japanese patient had surgery to remove her left breast due to primary malignant lymphoma. She then received hormone therapy in six cycles and completed it at the end of April 1999. The patient had a local recurrence, which was found by an ambulatory medical examination in June 1999. Tumor marker CA 15-3 was 85U at that time. She received chemotherapy consisting of Melphalan (4mg for 4 days) for the first week, Methotrexate (2.5 mg for 3 days) for the second week, Procailazine (100 mg for 3 days) for the third week and Cyclophophamide (50 mg every day) for the fourth week. In addition, she took 3 grams of Rice Bran Arabinoxylan Compound (RBAC) per day. Significant results had been obtained in the first cycle in that the tumor shrunk and the level of CA 15-3 declined to 45. After the second cycle, ambulatory treatment appeared possible, and the patient was able to leave the hospital on July 20, 1999. The patient had 4 cycles of chemotherapy in total. The tumor marker CA 15-3 consistently decreased and then stayed in normal range. A point deserving a special attention is the fact that the patient could continue ambulatory treatment with only minor adverse effects, despite her age (75). This is considered to be one of the benefits of RBAC. This may also indicate that RBAC had an effective and synergistic effect with the chemotherapy. Another interesting aspect in this case is that the patient did not lose her appetite and was able to maintain her energy during the course of chemotherapy. 13 Changes caused by RBAC Treatment It is worth noting that the patient did not have a loss of appetite and experienced little loss of energy during the administration of chemotherapeutics. Evaluation In this case, chemotherapy was used to prevent the recurrence of breast cancer. RBAC was added to avoid harming her immune system, which would also help enhance the effectiveness of chemotherapy. The result was totally satisfactory. In a RBAC study, it was found it can prevent NK cell activity decline caused by 5FU administration. In this case, it seems that the adverse effects of chemotherapy were mitigated by RBAC and the patient was able to maintain physical strength throughout the course of her treatments. Case Reports NAME/N.M. Hepatitis AGE/48 SEX/Male AREA/Japan Clinical Record and Treatment In early March 1996, the patient felt unusually lethargic and was ultimately diagnosed with chronic hepatitis (non-viral) and early diabetes at the H polyclinic. The patient checked in to the clinic on May 30, 1996. After rest and an intravenous injection for Major Minofargen C, his liver function temporarily stabilized and he was able to leave the clinic after a month. Thereafter, the patient experienced periodic deterioration in liver function despite continuing IV administration of Major Minofargen C, and he suffered from chronic hepatitis until the beginning of March 1997. The patient then started taking 3g of Rice Bran Arabinoxylan Compound (RBAC) per day (1g/dose) and his level of liver function increased to nearly the same level as they were at the beginning of therapy 12 days earlier. The enzyme levels gradually decreased, reaching the lowest value one month later. The patient's AST and ALT levels returned to normal one month afterwards. Presently, the patient's liver function has returned to normal and he is experiencing no other health-related problems. Changes caused by RBAC Treatment The patient's energy level increased after RBAC administration, and his unusual fatigue (especially in the afternoon) gradually abated. The patient was able to sleep and wake normally, had a good appetite, and appeared very healthy. Evaluation As indicated by the graph below, the AST and ALT levels temporarily increased after the administration of RBAC, before steadily decreasing and returning to normal. During RBAC administration, no special treatments were performed. These results suggest that RBAC protected the patient's liver and its immunopotentiation activity was effective. 14 Hepatitis B The clinical effectiveness of Rice Bran Arabinoxylan Compound (RBAC) in immunotherapy for patients with hepatitis B Dr. Tran Thi Minh Phuong (Former Vice Dean of Gastroenterology Department) Abstract: Hepatitis B virus (HBV) infection is a serious global health problem with devastating consequences of chronic hepatitis, cirrhosis, and hepatocellular carcinoma. More efficacious treatments such as mass immunization programs and safe injection techniques are essential for eliminating HBV infection and reducing global HBV-related morbidity and mortality. Antiviral therapy has been the primary treatment to date, however conventional treatment has undesirable side effects and continuous treatment can lead to the development of resistance. Additionally, antiviral medicines are costly, up to thousands of dollars per year, and are not widely available in many countries especially in the developing world. Rice Bran Arabinoxylan Compound (RBAC) is a food supplement that can be combined with conventional treatment to improve disease outcome. The following three cases describe patients with hepatitis B who were treated with the combination of conventional antiviral therapy and RBAC. In these cases, blood samples were taken to measure liver function and immunopotency, and the results were compared with clinical changes and imaging . Improvements were noted in most of the cases. Finally, some recommendations were provided to enhance the effectiveness of treatment progress. Key words: Hepatitis B virus infection, antiviral therapy, RBAC Methods The food supplement RBAC was ingested orally at dose of 1 pack/24h and combined with antiviral medicines and liver support supplements. The therapeutic effectiveness was assessed by measuring liver enzyme levels, immune parameters and ultrasound images. Results 1. Case 1 (male, 43 years, hepatitis B virus) The patient had been diagnosed with hepatitis B in 2000, presenting with symptoms of fatigue, slight fever, and dark urine. He underwent treatment with liver support supplements, antiviral therapy (Nucleozid) and RBAC (1 pack/24h). After 18 months of treatment, his biochemical test results improved. The test results and treatment progress are shown in table 1. Family history: this patient has a younger brother who also has HBeAg (+), and had been treated with antiviral medicine (Tenofovir) and RBAC 1 pack/24h. Table 1: Case 1 (male, 43 years, viral B hepatitis) Time of Clinical treatment symptom Biochemical tests AST ALT FP (U/l) (U/l) (ng/ml) Ultrasound test Viral detection tests HBsAg HBeAg Anti HBV DNA Hbc quantity (copies/ml) 11/2007 Fatigue, 78 84 (-) Gallbladder 15 (+) (-) (+) 6.91x106 Medicines (before yellow polyps; treatment) urine, gallbladder digestion duct: disorder hyper-echoic 1.1mm; texture 1 month of 42 60 - treatment Reducing liver enzyme medicine, - Antiviral medicine (Entecavir 0,5mg/24h), - RBAC 1 pack/24h 2 months 30 36 - of - RBAC 1 pack/24h 30 2.8x104 28 - of Antiviral - RBAC 1 pack/24h 32 30 1.84x10 2 Continuously used 2 of medications treatment months 15 months medicine (Entecavir 0,5mg/24h), treatment 12 months medicine (Entecavir 0,5mg/24h), treatment 6 months Antiviral Normal Normal 26.7 24.3 in 3 of treatment 3/4/2010 (-) Small (-) Unfound - Stop using antiviral gallbladder medicine polyps - RBAC plus 1 pack/24h 5/7/2010 26 18 (-) Indication for HBV immunization 2. Case 2 (male, 17 years old and younger brother, 15 years old) In February 2004, these patients presented with symptoms of fatigue, weight loss, and loss of appetite and were diagnosed with hepatitis B virus. Family history: their mother also has HBsAg (+) - Laboratory tests before treatment: 17 year old male 15 year old male - Biochemical tests: AST: 210 (UI/l); ALT: 180 (UI/l), FP - Biochemical tests: AST: 230 (UI/l); ALT: 210 (UI/l), (-) FP (-) - HBeAg (+), HBeAg (+), Anti Hbe (-) - HBeAg (+), HBeAg (+), Anti Hbe (-) - HBV DNA qualitative analysis (+++) - HBV DNA qualitative analysis (+++) - Ultrasound test: hyperechoic texture, enlarged spleen: - Ultrasound test: hyperechoic texture, enlarged spleen: 2cm below costal margin 1cm below costal margin 16 + Treatment: liver support supplement, viral inhibitor (Lamivudine 1 tablet/24h), and RBAC (1 pack/24h). - Laboratory tests after 6 months of treatment: 17 year old male 15 year old male - Liver enzymes: AST: 80 (UI/l); ALT: 42 (UI/l) - Liver enzymes: AST: 78 (UI/l) ; ALT: 46(UI/l) - HBeAg (+) - HBeAg (+) - HBV DNA qualitative analysis: (+) - HBV DNA qualitative analysis: (+) - Ultrasound test: hyperechoic texture, splenomegaly - Ultrasound test: hyperechoic texture, splenomegaly + Continuous treatment: liver support supplement, viral inhibitor (Lamivudine 1 tablet/24h), and RBAC (1 pack/24). - Laboratory tests after 12 months of treatment: 17 year old male 15 year old male - Liver enzymes: AST: 28 (UI/l); ALT: 40 (UI/l) - Liver enzymes: AST: 30 (UI/l); ALT: 42 (UI/l) - HBeAg (+) - HBeAg (+) - HBV DNA qualitative analysis: (+) - HBV DNA qualitative analysis: (+) - Ultrasound test: hyperechoic texture, splenomegaly - Ultrasound test: hyperechoic texture, splenomegaly + Continuous treatment: liver support supplement, viral inhibitor (Lamivudine 1 tablet/24h), and RBAC (1 pack/24h). - Laboratory tests after 24 months of treatment: 17 year old male 15 year old male - Liver enzymes: AST: 30 (UI/l); ALT: 26 (UI/l) - Liver enzymes: AST: 28 (UI/l); ALT: 24(UI/l) - HBeAg (+) - HBeAg (-) - HBV DNA qualitative analysis (+) - HBV DNA qualitative analysis - Ultrasound test: enlarged spleen, 1cm below costal () - Ultrasound test: normal spleen margin + Discontinued drug treatment, continued only with herbal medicine (Chanca Piedra) - February, 2010: 17 year old male 15 year old male - Weight loss, loss of appetite - Liver enzymes: AST: 28 (UI/l); ALT: 20(UI/l) - Liver enzymes: AST: 40 (UI/l); ALT: 86 (UI/l) - HBeAg (+), HBeAg quantity: 152.800 UI/l 6 - HBV DNA quantity: 10 copies/ml - Ultrasound test: hyperechoic texture, enlarged spleen below costal margin Treatment: Reduced liver enzyme medicine, viral Discontinue all medication inhibitor (Entecavir 0.5g/24h), RBAC (1 pack/24h) - 8/7/2010: 17 year old male 15 year old male - Liver enzymes: AST: 32 (UI/l); ALT: 30 (UI/l) - Liver enzymes: AST: 26 (UI/l); ALT: 18 (UI/l) - HBeAg (-) - HBeAg (-) 17 4 - HBV DNA quantity: 10 copies/ml - HBV DNA quantity: undetected - Ultrasound test: enlarged spleen below costal margin - HBeAg qualitative analysis: (-) - Ultrasound test: normal - Indication for HBV immunization - Patients continued herbal medicine (Chanca Piedra) during 6 years of treatment. 3. Case 3 (female, 23 years old, hepatitis B virus) The patient was diagnosed with hepatitis B virus one month after having a baby, presenting with symptoms of fatigue and loss of appetite. She also has a brother with HBsAg (+). She underwent treatment with liver support supplements, RBAC (1000 x 1 pack/24h) and continued breast feeding. The test results and treatment progress are shown in table 2. Table 2: Case 3 (female, 23 years, hepatitis B virus) Time of Clinical treatment symptoms 3/2006 Fatigue, (Before loss treatment) appetite Biochemical tests AST ALT FP (U/l) (U/l) (ng/ml) 100 120 of (-) Ultrasound test Hyper-echoic Viral detection tests HBsAg (+) HBeAg (+) Medicines Anti HBV DNA Hb quantity c (copies/ml) (-) 105 texture - Reduce liver enzyme medicine, - RBAC x 1 pack/24h - Keep breast feeding 2 months 60 38 - RBAC of pack/24h treatment - Keep x 1 breast feeding - Appropriate regime and resting 12/2006 32 28 (-) (+) - Antiviral medicine 9 months (Entecavir of 0,5mg/24h), treatment - RBAC x 1 x 1 pack/24h 5/2007 Nor-mal Nor-mal 103 (-) 14 months - RBAC pack/24h of treatment 9/2009 Nor-rmal Nor-mal (-) (+) Un-detected - Having 2nd baby - RBAC pack/24h pregnancy 18 x 1 during Conclusion and recommendations The safety of RBAC is easily accepted because it is extracted from rice bran. The current clinical cases further confirm the safety of RBAC. RBAC is used for immunotherapy to prevent a reduction in physical strength and appetite. The patients also reported, “When I take it, I feel better”. The combination of RBAC and antiviral medicines will have the maximum effect on hepatitis B patients who fall into the following criteria: + Patients who have high levels of liver enzymes and HBV DNA quantities. + Patients who are compliant with their medication schedule. The treatment is more effective on HBV patients who are HBeAg (+). Conversely, it is more difficult to treat HBV patients who are HBeAg (-); therefore taking 2 packs/24h is recommended for these patients. References: 1. D. Lavanchy (2004). Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. Journal of Viral Hepatitis 11(2): 97-10. 2. Lok AS, Hussain M, Cursano C et al (2000). Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen negative patients receiving lamivudine therapy. Hepatology 32(5): 1145–1153. 3. Lok AS, Zoulim F, Locarmini S et al (2007). Antiviral drug-resistant HBV standardization of nomendature and assys and recommendations for management. Hepatology 46(1): 254-265. 4. Ghoneum M (1998). Enhancement of Human Natural Killer Cell activitiy by modified Arabinoxylan from Rice Bran (MGN-3). INT.Immunotherapy 14(2): 89-99. 5. Yeo W, Johnson P J (2006). Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 43(2): 209-220. Hepatitis C NAME/H.Y. AGE/45 SEX/Male AREA/Japan History of Past Diseases and Treatments In 1999, the patient was found to have AST and ALT levels of more than 100 in an annual health exam. He had a complete medical checkup and was diagnosed with hepatitis C. He experienced significant fatigue and low energy. He was recommended interferon therapy, but refused for fear of adverse effects. Regular injections with Stronger Neo-Minophagen (an injectable glycyrrhiza) was the only alternative treatment he received. After six months, the level of liver function enzymes increased gradually. AST increased to a maximum of 215 and ALT to a maximum of 408, so he decided to try interferon therapy. Before starting interferon, he was given Rice Bran Arabinoxylan Compound (RBAC) at 3g per day and was put on a vegetable-focused diet for one month as an attempt to enhance immunopotency. After one month of RBAC treatment, AST and ALT were 20 and 28, respectively, therefore interferon therapy was cancelled. He continues taking RBAC at 3g daily and the AST and ALT levels have been maintained within normal limits. Evaluation Initial treatment was ineffective partly because he was in the habit of smoking and drinking. Since he gave up 19 smoking and drinking and switched to a diet centering on vegetables, RBAC showed a significant and swift effect. The immunopotentiating effect (activation of NK cells and production of interferon) and liver-protecting effect of RBAC resulted in a decrease of the viral count and eliminated liver inflammation. NAME/T.K. AGE/66 SEX/Female AREA/Japan History of Past Diseases and Treatments In 1990, the patient was diagnosed with hepatitis C, but had no specific symptoms. In July 1995, a health checkup revealed an abnormality in the liver. She had a complete medical checkup at the general hospital, which revealed a 3 cm liver cancer lesion. The treatment regimen involved infusing ethanol into the affected area. The patient was given Rice Bran Arabinoxylan Compound (RBAC) at 3 g daily to reduce the adverse effect of the ethanol therapy and protect the liver. Ethanol therapy was repeated seven times, and adverse effects such as fever, nausea and anorexia were mild. The AFP value also decreased from 602.5 to 7.2, so the patient was discharged on the last day of September. Although the AST and ALT values at discharge were 60 and 85, respectively, the examination performed in February 1996 showed that the area treated with ethanol was necrotized, the tumor disappeared completely and liver function normalized. Changes caused by ingestion of RBAC Within three days of treatment with RBAC, the patient began to improve and regained her appetite. She felt she could endure the ethanol therapy with her increased physical strength and wished to recover her health completely. Evaluation Ethanol therapy is performed to solidify tumors with ethanol to prevent further growth, but it may cause inflammation and pain in surrounding tissues. The immunopotentiating and liver-protective effect of RBAC reduced the adverse effects of ethanol therapy and increased its effectiveness. NAME/T.M. AGE/60 SEX/Male AREA/Japan History of Past Diseases and Treatments The patient began to feel malaise and fatigue in his lower limbs in April 1996. These symptoms persisted, so he visited a hospital in September to undergo a complete medical checkup. Both the AST and ALT levels were about 400 and he was diagnosed with viral hepatitis C. He continued rest and dietary therapy and began receiving treatment with interferon in June 1997. At this point in time, the AST and ALT levels were both between 180 and 190. In addition to interferon, the patient took Rice Bran Arabinoxylan Compound (RBAC) at 3 g daily. He remained in the hospital for the first two weeks of interferon treatment. During this period, no adverse effects were observed except a fever of 39℃ or more. He was treated with interferon therapy for six months until late December, visiting the hospital three times weekly. No adverse effects or attacks of fever occurred during this course, except for occasional bouts of malaise associated with interferon injection. The AST and ALT values were within normal limits. Examinations in January and May, 1998, revealed no viral reaction and showed complete remission. He is now taking RBAC at 2 g daily to prevent recurrence. Changes caused by ingestion of RBAC Interferon is thought to cause strong adverse effects such as chills, anorexia and fever, however the patient did not have serious adverse effects. 20 Case Reports NAME/T.T. Diabetes AGE/55 SEX/Male AREA/Japan Clinical Record and Treatment The patient was diagnosed with insulin-dependent diabetes mellitus in 1994. His blood sugar level was maintained between 157~160 mg/dl by taking 12 units of insulin per day. After the patient began taking 3g of Rice Bran Arabinoxylan Compound (RBAC) per day, he was able to reduce the insulin dosage to 6 units. Changes caused by ingestion of RBAC On the fifth day of RBAC treatment, the patient became hypoglycemic so insulin administration was reduced to 10 units. On the sixth day, the patient became hypoglycemic again and the insulin dosage was reduced to 8 units. The th third hypoglycemic event occurred on the 25 day, and the insulin dosage was then reduced to 6 units. Since then, there have been reoccurrences of hypoglycemia. The patient now feels cured of diabetes and has declared that he feels his life is worth living again. NAME/K.N. AGE/66 SEX/Male AREA/Japan History of Past Diseases and Treatments In June 1993, the patient was finding that he had to get up several times during the night to urinate and had to drink water frequently to satisfy his constant thirst. He went to the hospital for an examination and was diagnosed with diabetes. His blood sugar level was 320 mg/dl. In September of that year, he was hospitalized and began to receive treatment. His blood sugar level did not decrease until March 1994, when he was discharged, because he developed hepatopathy, a possible complication from diabetes which delayed recovery. He continued treatment with insulin injections at hospital visits but the fatigue did not disappear. He also had occasional attacks of asthma and was feeling worse. At this point, he began taking Rice Bran Arabinoxylan Compound (RBAC) at a dose of 3 g daily. In May, two months after starting to take RBAC, the blood sugar levels decreased to 110 mg/dl and insulin was no longer necessary. Symptoms of asthma also began to improve and he had no asthma attacks from the autumn of 1994 to the spring of 1995. He is now feeling better and working every day. He still takes RBAC 1 g daily to maintain health. Changes caused by ingestion of RBAC Seven days after starting to take RBAC, his malaise subsided and the patient had a comfortable awakening. Symptoms of asthma also ameliorated and the sense of tightness in his throat disappeared. NAME/Y.E. AGE/58 SEX/Male AREA/Japan History of Past Diseases and Treatments In the middle of November, 1996, the patient went to a nearby hospital and presented with abnormal fatigue. His blood sugar level was 300 mg/dl and his glycohemoglobin (HbA1c) level was 9.8 and so was diagnosed with diabetes. He also had complications from the disease; he was aware that he had been eating too many sweets since the summer, but he attributed it to his fatigue. For the next month, he was put on a restricted diet and therapeutic exercise that consisted of one hour of fast walking, but these therapies were not beneficial. Because he was told that he had no choice but to undergo treatment with insulin, he went to K Hospital for additional treatments. K Hospital recommended taking Rice Bran Arabinoxylan Compound (RBAC) at 3 g daily in addition to conventional treatment 21 with a restricted diet and exercise. One month after starting treatment with MGN-3, the blood sugar level decreased to 98 mg/dl and the glycohemoglobin level to 7.2. He is now taking 1g RBAC daily. Changes caused by ingestion of RBAC He began to feel relief from his fatigue seven days after starting RBAC therapy. He no longer craved sweets and the numbness in his limbs decreased day-by-day. Case Reports Herpes NAME/R.S. AGE/26 SEX/Female AREA/Germany 16/02/2007-02/03/2007: Hospitalized 16/02/2007: Radiology: cranial MRI. Clinical indications: Lethargic patient, significant migraine with aura. Assessment of the headache: visualization of left sided meningoencephalitis, temporomesial emphasis, e.g. transmigration to left maxillary sinus. Recent cortical ischemia in temporal cortex. Because of localization, herpes encephalitis must be ruled out stat. An immediate referral to the emergency room was advised. No signs of distress. (the definition is “prison”). 22/02/2007: Confirmed diagnosis of herpes meningoencephalitis, left temporal. (A86) Anamnesis (preliminary case history of a medical or psychiatric patient): The patient went to the emergency room on 12.02.07 because of a massive headache spanning the neck to the top of the head, lasting three days. On 12.02.07 she noticed a short-term right sided scotoma (partial visual interference), intermittent blurred vision with no other coexisting vegetative symptoms (such as insomnia). An antiviral therapy with Zovirax by infusion was initiated. 02/03/2007: Initiate treatment of 3g of Rice Bran Arabinoxylan Compound (RBAC) daily for eight weeks. 23/04/2007: Evaluation of condition after herpes meningoencephalitis: approximately 3 cm sized area of damage in the left temporal region with continued low grade cortical blood-brain barrier disorder. No other diffusion disorders. Continued accompanying moderate grade, localized soft tissue edema. No signs of significant compression of collateral brain structures. Furthermore,in the supra- as well as infratentorial there was an absence of brain parenchyma signal changes. Medical evaluation: small damaged area in left-temporal region with only moderate grade accompanying edema. No significant compression of collateral brain structure. No ischemia. No intracranial bleeding 20/06/2007: Diagnosis: S/P herpes meningoencephalitis on left side, temporal (A86). Confirmed latent sensorimotor hemiplegic symptoms left side (G81.9) Clinical evaluation: S/P herpes meningoencephalitis remains detectable on neurological test with latent sensorimotor hemiplegic symptoms on left side. Activities of daily living were not impacted. No further therapy is necessary. February 2008: With exception of minor problems with short-term memory, the patient is free of complaints. 22